Detalles de la búsqueda
1.
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.
Cell
; 173(3): 611-623.e17, 2018 04 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-29656891
2.
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.
Immunity
; 55(3): 527-541.e5, 2022 03 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35231421
3.
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 612-624, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35390339
4.
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.
Int J Cancer
; 151(8): 1335-1344, 2022 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35603906
5.
Indocyanine green for sentinel lymph node detection in early breast cancer: Prospective evaluation of detection rate and toxicity-The FLUOBREAST trial.
Breast J
; 26(12): 2357-2363, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33094498
6.
How molecularly similar are primary and metastatic tissues in renal cell carcinoma? - Authors' reply.
Lancet Oncol
; 23(7): e317, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35772459
7.
Optimal molecular selection to benefit from nivolumab-ipilimumab in clear-cell renal cell carcinoma.
Lancet Oncol
; 23(7): e318, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35772460
8.
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
BJU Int
; 118(6): 890-901, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27417418
9.
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Acta Oncol
; 53(1): 103-12, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23421954
10.
Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.
Oncology
; 85(1): 8-13, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23797151
11.
Longitudinal Study of Advanced Non-Small Cell Lung Cancer with Initial Durable Clinical Benefit to Immunotherapy: Strategies for Anti-PD-1/PD-L1 Continuation beyond Progression.
Cancers (Basel)
; 15(23)2023 Nov 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38067291
12.
Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Eur J Cancer
; 186: 83-90, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37054556
13.
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Clin Cancer Res
; 29(7): 1279-1291, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36374555
14.
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.
Cancer Res
; 83(17): 2952-2969, 2023 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335139
15.
Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/- Docetaxel.
Cancers (Basel)
; 14(3)2022 Feb 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35159082
16.
First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
Cancers (Basel)
; 13(21)2021 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34771710
17.
Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis.
Cancers (Basel)
; 12(6)2020 Jun 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-32599839
18.
[Impact of molecular signatures on the choice of systemic treatment for metastatic kidney cancer]. / Impact des signatures moléculaires sur le choix du traitement systémique du cancer du rein métastatique.
Bull Cancer
; 107(5S): S24-S34, 2020 Jun.
Artículo
en Francés
| MEDLINE | ID: mdl-32620204
19.
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
Bull Cancer
; 107(5S): eS8-eS15, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32620213
20.
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer.
Bull Cancer
; 107(5S): eS22-eS27, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32620212